Reagenti e strumenti per immunologia, biologia cellulare e biologia molecolare
 
> N-acetylcysteine amide [38520-57-9]

N-acetylcysteine amide [38520-57-9]

Stampa Stampa
Entra

Cat# orb1301727-500mg

Size : 500mg

Marca : Biorbyt


N-acetylcysteine amide

SKU: orb1301727

Description

N-acetylcysteine amide

Research Area

Immunology & Inflammation, Metabolism Research, Pharmacology & Drug Discovery, Signal Transduction

Images & Validation

−
N-acetylcysteine amide

Key Properties

−
CAS Number38520-57-9
MW162.21
Purity≥98% (May vary between batches)
FormulaC5H10N2O2S
SMILESCC(=O)N[C@@H](CS)C(N)=O
TargetReactive Oxygen Species|||ROS
SolubilityDMSO:245 mg/mL (1510.39 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (30.82 mM);H2O:100 mg/mL (616.48 mM)

Bioactivity

−
In Vivo
METHODS: To assay antitumor activity in vivo, LAT1-IN-1 (200 mg/kg) was administered intravenously to BALB/c nude mice bearing KYSE150 tumors once daily for 14 days. RESULTS: Daily treatment with LAT1-IN-1 for 14 consecutive days significantly delayed tumor growth.
In Vitro
METHODS: Human esophageal cancer cells KYSE30 and KYSE150 were treated with LAT1-IN-1 (1-100 mM) for 3 days, and cell viability was measured by MTT assay. RESULTS: LAT1-IN-1 treatment inhibited cell proliferation in a dose-dependent manner. METHODS: HTR8 SVneo, JEG-3 and JAR cells were treated with LAT1-IN-1 (0.1-4 µM) for 24 h, and the expression levels of target proteins were detected by Western Blot. RESULTS: LAT1 protein was significantly reduced after 24 h LAT1-IN-1 treatment, and LAT1-IN-1 could directly regulate the expression of LAT1.
Cell Research
To determine effectiveness of NACA and NAC in protection of H9c2 cells from DOX-induced toxicity, cells were treated with NACA or NAC at 0.75 mM for 2 h followed by exposure to freshly prepared cell culture medium with DOX in presence or absence of NACA or NAC at designated concentrations. The concentrations of DOX were 0.25 μM, 0.75 μM, 2 μM, 5 μM, 20 μM, and 100 μM. The exposure durations were 24 h, 48 h, or 48 h. Cells incubated with NACA or NAC alone were used as the control.
Animal Research
rats were randomly divided into three groups (n=6-8 animals/group): N-acetylcysteine amide loaded pump (18.5 mg/kg/hr) and a single 150 mg/kg bolus intraperitoneal (IP) injection of NACA given (30 min post-injury) N-acetylcysteine amide (18.5 mg/kg/hr) loaded pump and a single 150 mg/kg bolus injection of N-acetylcysteine amide given IP (30 min post-injury) Vehicle loaded pump and single vehicle bolus injection given IP (30 min post-injury). Following random distribution of all animals into one of the three previous groups, experimenters were blinded to treatment group. The osmotic mini pumps were assembled and implanted immediately after injury and remained in the animals for 7 days

Storage & Handling

−
Storage-20°C
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

−
inhibit, N acetylcysteine amide, Nacetylcysteine amide, N-Acetylcysteine amide, N-acetylcysteine Amide, Inhibitor, ReactiveOxygenSpecies, Reactive Oxygen Species, ROS
−
  • N-acetylcysteine amide

    N-acetylcysteine amide [orb1220989]

    >98% (HPLC)

    38520-57-9

    282.34

    C8H14N2O5S2

    2 mg, 5 mg, 10 mg, 100 mg, 500 mg, 25 mg, 50 mg, 1 g
  • N-Acetylcysteine amide

    N-Acetylcysteine amide [orb1966049]

    38520-57-9

    162.21

    C5H10N2O2S

Compound Identifiers

PubChem CID
10176265 ↗

Key Properties

−
No computed properties available.

Protocol Information